Juchems M S, Ernst A S, Kornmann M, Barth T F, Kramer K, Brambs H-J, Aschoff A J
Klinik für Diagnostische und Interventionelle Radiologie, Universitätskliniken Ulm, Germany.
Rofo. 2009 Dec;181(12):1168-74. doi: 10.1055/s-0028-1109356. Epub 2009 Apr 30.
Neoadjuvant therapy may reduce local rectal cancer recurrence after total mesorectum extirpation. This study was performed to assess whether multi-detector row CT (MDCT) is capable of reliably differentiating UICC I (surgery) from UICC II-IV (neoadjuvant therapy).
29 patients underwent preoperative MDCT of the abdomen in a portal venous phase. Two blinded readers independently evaluated the datasets on a dedicated workstation using axial and coronal reformations. Local tumor extension (T), nodal status (N) and distant metastases (M) were evaluated and the UICC stage was determined. Findings were correlated with postoperative histology.
Histologically, 9 patients were UICC I; 20 UICC > I (II: 7; III: 11; IV: 2). Reader 1 correctly identified 3 / 9 as UICC I, overstaged 6 / 9, and correctly staged 20 / 20 as UICC > I. Reader 2 correctly identified 4 / 9 as UICC I, overstaged 5 / 9, understaged 4 / 20 and correctly staged 16 / 20 as UICC > I (PPV UICC I 100 % [50 %] reader 1 [reader 2], NPV 77 % [76 %], accuracy 79 % [69 %]). Reasons for overstaging by reader 1 (reader 2) included false-positive lymph nodes (LN) in 5 (5), overgrading T 1 tumors as T 3 in 1(0), and T overgrading in 4 / 5 (2 / 5) patients with false-positive LN.
MDCT failed to reliably identify UICC I in rectal cancer patients. Therefore, a strategy based solely on MDCT to identify patients who would benefit from neoadjuvant therapy does not seem appropriate.
新辅助治疗可能会降低全直肠系膜切除术后局部直肠癌的复发率。本研究旨在评估多排螺旋CT(MDCT)能否可靠地区分国际抗癌联盟(UICC)I期(手术治疗)和UICC II-IV期(新辅助治疗)。
29例患者在门静脉期接受了腹部术前MDCT检查。两名盲法阅片者在专用工作站上使用轴位和冠状位重组图像独立评估数据集。评估局部肿瘤扩展情况(T)、淋巴结状态(N)和远处转移情况(M),并确定UICC分期。将检查结果与术后组织学结果进行对比。
组织学检查显示,9例为UICC I期;20例为UICC > I期(II期:7例;III期:11例;IV期:2例)。阅片者1正确识别出3/9例为UICC I期,将6/9例过度分期,将20/20例正确分期为UICC > I期。阅片者2正确识别出4/9例为UICC I期,将5/9例过度分期,将4/20例分期过低,将16/20例正确分期为UICC > I期(UICC I期的阳性预测值为100% [50%],阅片者1 [阅片者2],阴性预测值为77% [76%],准确率为79% [69%])。阅片者1(阅片者2)过度分期的原因包括5例(5例)出现假阳性淋巴结(LN),1例(0例)将T1期肿瘤过度分级为T3期,以及4/5例(2/5例)有假阳性LN的患者出现T分级过高。
MDCT未能可靠地识别直肠癌患者的UICC I期。因此,仅基于MDCT来识别能从新辅助治疗中获益的患者的策略似乎并不合适。